Fulgent Genetics (FLGT) Azione Prezzo
Fulgent Genetics Prezzo
Negli ultimi 11 anni Fulgent Genetics ha aumentato il fatturato del 65,3% all'anno, raggiungendo 322,67 Mio. USD. L'utile per azione è cresciuto del 532,4% all'anno negli ultimi 3 anni. Per Fulgent Genetics, il margine netto del -18,8% risulta in calo rispetto al 10,5% di alcuni anni fa. Il target di prezzo di consenso a 12 mesi per Fulgent Genetics è 19,00 USD, circa il 15,4% sotto il prezzo attuale di mercato. Su 6 analisti, 0 valutano il titolo come acquisto — nel complesso un consenso Vendere.
Fulgent Genetics Prezzo delle azioni
Accedi a questi dati tramite l’API Eulerpool
100.000 richieste/mese gratis · nessuna carta di credito
Fulgent Genetics Azione e analisi azionaria
Domande frequenti sull'azione Fulgent Genetics
The business model of Fulgent Genetics Inc focuses on providing comprehensive genetic testing solutions. The company leverages its proprietary technology platform to offer a wide range of genetic tests, empowering healthcare professionals and patients with accurate and actionable information regarding inherited diseases, cancer predisposition, and other genetic conditions. Fulgent Genetics Inc's business model revolves around offering high-quality testing services and genetic analysis for individuals, healthcare providers, researchers, and pharmaceutical companies. By combining advanced technology and expertise in genetics, Fulgent Genetics Inc aims to support personalized medicine and improve patient outcomes through precise diagnostics and genetic insight.
Fulgent Genetics Inc is primarily active in the healthcare and biotechnology industries.
The main competitors of Fulgent Genetics Inc in the market include companies like Invitae Corporation, Myriad Genetics Inc, and Genomic Health Inc.
Fulgent Genetics Inc is a leading genetic testing company headquartered in California, United States. Established in 2011, Fulgent Genetics has rapidly emerged as a trusted provider of comprehensive genetic testing solutions. The company specializes in Next Generation Sequencing (NGS) and offers a wide range of genetic tests for various applications, including cancer screening, carrier screening, and hereditary diseases. Fulgent Genetics is committed to leveraging advanced technology and bioinformatics to deliver accurate and actionable results. With its innovative approach and dedication to quality, Fulgent Genetics has become a recognized name in the field of genetic testing, serving healthcare professionals, researchers, and individuals worldwide.
Fulgent Genetics Inc has achieved several significant milestones. The company successfully developed a proprietary technology platform, called Next Generation Sequencing (NGS), which has revolutionized genetic testing. Fulgent Genetics Inc has also formed strategic partnerships with leading healthcare providers and institutions, expanding its reach and impact within the industry. The company has received numerous accreditations and certifications, highlighting its commitment to ensuring the highest quality standards in genetic testing services. Additionally, Fulgent Genetics Inc has experienced remarkable financial growth, with increasing revenue and consistent profitability, making it a leading player in the field of genetic testing.
Fulgent Genetics Inc is primarily present in several countries and regions worldwide. The company has a significant presence in the United States, where it is headquartered and operates its main operations. Fulgent Genetics Inc also extends its presence to international markets, including countries in Europe, such as Germany, France, and the United Kingdom. Additionally, the company has expanded its reach in Asia, with a presence in countries like China and Japan. Fulgent Genetics Inc's global presence allows it to serve a diverse customer base and tap into various market opportunities.
Fulgent Genetics Inc represents values of innovation, integrity, and excellence in the field of genetic testing and diagnostics. The company is committed to providing accurate and reliable results to healthcare providers and patients, helping to improve patient outcomes and personalized medicine. Fulgent Genetics' corporate philosophy revolves around staying at the forefront of genetic technology advancements, continuously expanding its test menu, and maintaining a strong focus on customer satisfaction. With its state-of-the-art laboratories and a team of highly trained professionals, Fulgent Genetics Inc remains dedicated to delivering high-quality genetic testing solutions.
Gli analisti fissano attualmente un prezzo obiettivo medio di 19,00 USD per l’azione Fulgent Genetics (mediana: 19,00 USD), pari a -15,4 % rispetto all’ultimo prezzo. Il consenso si basa su 6 giudizi di analisti.
6 analisti valutano attualmente l’azione Fulgent Genetics: 0 raccomandano l’acquisto, 3 la tenuta e 3 la vendita. Per il 2026 gli analisti si aspettano per Fulgent Genetics ricavi pari a 331,70 Mio. USD e un utile per azione di -2,28 USD.
Convertita al tasso di cambio attuale, l’azione Fulgent Genetics quota 20,14 EUR (22,47 USD).
L’azione Fulgent Genetics (FLGT) è quotata su 4 borse, tra cui: NASDAQ (FLGT), Frankfurt (7F0.F), München (7F0.MU), Düsseldorf (7F0.DU).
The company Fulgent Genetics Inc is a leading provider of genetic testing services and solutions. Founded in 2011, the company specializes in the development and commercialization of advanced genetic tests and procedures to improve diagnostic and research applications in medicine, life sciences, and agriculture. Fulgent Genetics' business model is based on developing innovative genetic tests and procedures based on the latest scientific knowledge and technologies. The company offers a wide range of genetic tests and procedures that allow for accurate diagnosis of genetic diseases. Their products include prenatal genetic tests for early detection of congenital anomalies, cancer genetics tests for identifying cancer-causing gene mutations, tests for rare genetic diseases, carrier tests for detecting carriers of genetic diseases, and pharmacogenomics tests for personalized medicine. Fulgent Genetics operates two business segments: diagnostics and research. Under the diagnostics segment, the company provides genetic tests for clinical diagnosis of genetic diseases in medicine. These tests are used by patients, physicians, and healthcare organizations to identify genetic risks, diagnose diseases, and determine treatment options. Under the research segment, the company offers products for research institutions and companies working on researching genetic connections for the development of new treatment methods. The company has developed a user-friendly online portal that allows customers to easily access its services. The portal provides an intuitive interface for ordering genetic tests and monitoring the progress of test results. Fulgent Genetics also offers customization services for specific tests to meet the different needs of customers. Fulgent Genetics aims to become a preferred partner for healthcare organizations, research institutions, and companies for genetic diagnostic and research services. The company strives to continually improve its research and development capabilities and explore growth opportunities through expansion strategies and new partnerships. In summary, Fulgent Genetics offers a wide range of innovative and user-friendly genetic tests and procedures that enable accurate diagnosis of genetic diseases. The company aims to become a preferred partner for healthcare organizations, research institutions, and companies for genetic diagnostic and research services by continually improving its research and development capabilities and exploring growth opportunities through expansion strategies and new partnerships.
Il attesa fatturato di Fulgent Genetics ammonta a 331,70 Mio. USD. Questo dato si basa sui dati finanziari attuali e riflette lo sviluppo commerciale dell'azienda.
Il attesa profitto di Fulgent Genetics ammonta a -70,17 Mio. USD. L'utile netto riflette la redditività dell'azienda dopo la deduzione di tutti i costi.
Il rapporto prezzo/utili (P/E) di Fulgent Genetics è attualmente -9,86. Il rapporto P/E confronta il prezzo attuale dell'azione con l'utile per azione e aiuta gli investitori a valutare la valutazione dell'azione Fulgent Genetics.
Il rapporto prezzo/fatturato (P/S) di Fulgent Genetics è attualmente 2,08. Il rapporto P/S confronta la capitalizzazione di mercato con il fatturato annuo e funge da indicatore di valutazione dell'azione Fulgent Genetics.
Il Quality Score AlleAktien per Fulgent Genetics è 3/10.
L'ISIN di Fulgent Genetics è US3596641098. L'ISIN (International Securities Identification Number) è un codice identificativo univoco a livello mondiale per i titoli.
Il WKN di Fulgent Genetics è A2AS4N. Il WKN (Wertpapierkennnummer) è un codice identificativo tedesco a sei cifre per i titoli.
Il ticker di Fulgent Genetics è FLGT. Con questo simbolo di borsa vengono negoziate le azioni Fulgent Genetics in borsa.
Azione Fulgent Genetics
Gruppo di pari di Fulgent Genetics
Fulgent Genetics Ticker
Fulgent Genetics FIGI
Altre metriche e analisi di Fulgent Genetics in Deep Dive.
La nostra analisi azionaria dell'azione Fulgent Genetics include importanti indicatori finanziari come il fatturato, l'utile, il P/E, il P/S, l'EBIT, oltre a informazioni sul dividendo. Inoltre, esaminiamo aspetti come le azioni, la capitalizzazione di mercato, il debito, il patrimonio netto e le passività di Fulgent Genetics. Se state cercando informazioni più dettagliate su questi temi, sulle nostre sottopagine offriamo analisi approfondite: